" class="no-js "lang="en-US"> Gregory M. Glenn Archives - Medtech Alert
Saturday, March 25, 2023

Breaking News

Illumina and GenoScreen Launch Next Generation Sequencing Innovation to Eliminate Tuberculosis in Africa Celyad Oncology Appoints Georges Rawadi as Its New CEO Companion Spine Closes $60.1 Million Series A Funding Round EVERSANA® Announces Partnership with ChemoMouthpiece, LLC to Support U.S. Launch & Commercialization of Medical Device to Help Cancer Patients Manage and Treat Oral Mucositis Vividion Therapeutics Promotes Matt Patricelli to Chief Scientific Officer GT Medical Technologies Raises $45 Million in Oversubscribed Series C Financing Led by Gilde Healthcare Genprex CEO Commends FDA’s Initiative to Accelerate Approval Process for Gene Therapies OliX Pharmaceuticals Receives Regulatory Approval to Commence Phase 1 Clinical Trial of Treatment of Androgenic Alopecia Bayer Expands Global Clinical Program for NUBEQA® (darolutamide) in Prostate Cancer BIOTECanada Welcomes Government of Canada’s Strategy on Improving Access to Care for Patients with Rare Diseases

Sort by:

Date

Top Post

FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb) for the Treatment of Alzheimer's Disease | MTA

FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb) for the Treatment of Alzheimer's Disease

Eisai and Biogen announced today that the US Food and Drug Administration (FDA) has accepted […]

Read more

COVID-19

 Novavax Announces Extended Durability of Protection Against Infection and Disease in United Kingdom COVID-19 Vaccine Phase 3 Clinical Trial | Pharmtech Focus

Novavax Announces Extended Durability of Protection Against Infection and Disease in United Kingdom COVID-19 Vaccine Phase 3 Clinical Trial

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious […]

Clinical Trials

 Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial | Pharmtech Focus

Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial

Novavax, Inc. (Nasdaq: NVAX), today announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% […]

Clinical Trials

 Novavax Announces Positive Preclinical Data for Combination Influenza and COVID-19 Vaccine Candidate (NanoFlu/NVX-CoV2373) | Pharmtech Focus

Novavax Announces Positive Preclinical Data for Combination Influenza and COVID-19 Vaccine Candidate (NanoFlu/NVX-CoV2373)

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced […]

Clinical Trials

 NEJM Publishes Phase 2b Clinical Trial Results Demonstrating Efficacy of Novavax COVID-19 Vaccine Against the B.1.351 Variant | Pharmtech Focus

NEJM Publishes Efficacy of Novavax Vaccine Against B.1.351 Variant

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced […]

Clinical Trials

 Novavax Initiates Pediatric Expansion for Phase 3 Clinical Trial of COVID-19 Vaccine | Pharmtech Focus

Novavax Initiates Pediatric Expansion for Phase 3 Clinical Trial of COVID-19 Vaccine

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced […]

Clinical Trials

 Malaria Vaccine Phase 2b Clinical Trial Results Published in Preprints with The Lancet | Pharmtech Focus

Malaria Vaccine Phase 2b Clinical Trial Results Published in Preprints with The Lancet

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced […]

  1. Illumina and GenoScreen Launch Next Generation Sequencing Innovation to Eliminate Tuberculosis in Africa

    Diseases

     Read more
  2. Celyad Oncology Appoints Georges Rawadi as Its New CEO

    Appointments

     Read more
  3. Companion Spine Closes $60.1 Million Series A Funding Round

    Fundraising

     Read more
  4. EVERSANA® Announces Partnership with ChemoMouthpiece, LLC to Support U.S. Launch & Commercialization of Medical Device to Help Cancer Patients Manage and Treat Oral Mucositis

    News

     Read more
  5. Vividion Therapeutics Promotes Matt Patricelli to Chief Scientific Officer

    Appointments

     Read more